Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
|Videos|March 14, 2011
Dr. Pearlstone on Biomarker Testing in the Community
Author(s)David Pearlstone, MD
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting
Advertisement
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on Biomarker Testing in the Community Setting.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
4
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
5